Defendant
1 case as defendant.
Neurent Medical Limited is an Irish MedTech company founded in 2015 by David Townley and Brian Shields, with its headquarters in Galway, Ireland, and U.S. operations in Braintree, Massachusetts. It operates as a privately held company. The company had approximately 35 to 76 employees as of early 2026. Its estimated annual revenue is around $3.5 million.
Neurent Medical specializes in developing smart devices for the minimally invasive treatment of chronic inflammatory sino-nasal diseases. Their primary product is the NEUROMARK® System, a hand-held radio-frequency device that uses impedance-controlled radiofrequency technology to target and disrupt hyperactive autonomic nerves in the nasal cavity. This treatment aims to alleviate symptoms of chronic rhinitis, such as nasal congestion, runny nose, and sneezing, by addressing the underlying inflammation. Neurent Medical received U.S. FDA clearance for its Neuromark system in 2021 and for a next-generation system in early 2025.
The company's patent litigation posture is defensive, as indicated by its single tracked case as a defendant and zero as a plaintiff. Neurent Medical Limited is an operating company that defends its intellectual property.
Neurent Medical Limited is currently involved in one tracked case: Aerin Medical Inc. v. Neurent Medical Limited. This case, filed on June 25, 2025, is before the Patent Trial and Appeal Board (PTAB), where Aerin Medical Inc. is challenging claims 1-30 of Neurent Medical's U.S. Patent No. 12,096,973. The patent at issue, titled "Neuromodulation Device for Treating Rhinitis," discloses a method for treating rhinitis, congestion, and rhinorrhea by delivering radiofrequency energy to the sino-nasal cavity. There has also been related litigation in the U.S. District Court for the District of Delaware concerning a prosecution bar related to nasal treatment technologies between Aerin Medical Inc. and Neurent Medical Inc.Neurent Medical Limited is a privately held Irish MedTech company, founded in 2015 by David Townley and Brian Shields. The company is headquartered in Galway, Ireland, with its U.S. operations based in Braintree, Massachusetts. As of early 2026, Neurent Medical had approximately 35 to 76 employees and an estimated annual revenue of around $3.5 million.
Neurent Medical develops smart medical devices for the minimally invasive treatment of chronic inflammatory sino-nasal diseases. Its flagship product is the NEUROMARK® System, a hand-held radio-frequency device. This system utilizes impedance-controlled radiofrequency technology to precisely target and disrupt hyperactive autonomic nerves in the nasal cavity, aiming to provide relief from symptoms of chronic rhinitis such as congestion, runny nose, and sneezing. The company received U.S. FDA clearance for its original Neuromark system in 2021 and for a next-generation version in early 2025.
Neurent Medical's patent litigation posture is defensive, as evidenced by its sole appearance as a defendant in tracked cases and no instances as a plaintiff. This indicates that it operates as a company producing and selling products and services, rather than asserting patents as its primary business model.
The company is currently involved in one notable tracked case, Aerin Medical Inc. v. Neurent Medical Limited. This proceeding, filed on June 25, 2025, before the Patent Trial and Appeal Board (PTAB), involves Aerin Medical Inc. challenging the patentability of claims 1-30 of Neurent Medical's U.S. Patent No. 12,096,973. This patent describes a "Neuromodulation Device for Treating Rhinitis," focusing on methods for treating rhinitis, congestion, and rhinorrhea by delivering radiofrequency energy to the sino-nasal cavity.
This PTAB case was an Inter Partes Review petition filed by Aerin Medical Inc. against Neurent Medical Limited. The petition was not instituted on procedural grounds and was terminated on November 20, 2025.